← The Wire
GERNNasdaq
GERON CORP
Pharmaceutical Preparations · DE · CIK 886744
Develops and commercializes a telomerase inhibitor for blood cancers
red 8-K · 90d
$738M
Market cap
$1.30
Last close
-1.5%
1D
-3.0%
5D
14.6M
Volume
Price · last 39 sessions-17.2%
May 4L $1.10 · H $1.65Jun 29
369
Total filings
May 27, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 27, 202610-Q10-QMay 6, 2026DEFA14ADEFA14AApr 7, 2026DEF 14ADEF 14AApr 7, 20268-KExecutive ChangeMar 26, 202610-K10-KMar 2, 20268-KResults of OperationsFeb 25, 20268-KReg FD DisclosureJan 12, 20268-KMaterial AgreementJan 6, 20268-KExit / Disposal CostsDec 16, 202510-Q10-QNov 7, 20258-KResults of OperationsNov 5, 20258-KExecutive Change · Reg FD DisclosureOct 14, 20258-KExecutive ChangeAug 6, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KExecutive Change · Shareholder VoteMay 27, 202510-Q10-QMay 7, 20258-KResults of OperationsMay 7, 2025DEFA14ADEFA14AApr 8, 2025DEF 14ADEF 14AApr 8, 20258-K/AExecutive ChangeMar 17, 20258-KExecutive ChangeMar 11, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 26, 20258-KResults of Operations · Reg FD DisclosureJan 13, 2025SC 13GSC 13GNov 14, 202410-Q10-QNov 7, 20248-KMaterial Agreement · Agreement TerminatedNov 7, 202410-Q10-QAug 8, 20248-KAcquisition / Disposition · Results of OperationsAug 8, 20248-KCompany UpdateJun 7, 20248-KShareholder VoteMay 13, 202410-Q10-QMay 2, 20248-KResults of OperationsMay 2, 2024DEFA14ADEFA14AMar 27, 2024DEF 14ADEFINITIVE PROXY STATEMENTSMar 27, 20248-KMaterial AgreementMar 20, 2024424B5424B5Mar 20, 20248-KCompany UpdateMar 19, 20248-KCompany UpdateMar 14, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 28, 2024SC 13GSCHEDULE 13GFeb 13, 20248-KCompany UpdateJan 30, 20248-KResults of Operations · Reg FD DisclosureJan 8, 20248-KMaterial Agreement · New Debt / ObligationDec 15, 20238-KExecutive ChangeNov 28, 2023424B5424B5Nov 2, 20238-KMaterial Agreement · Results of OperationsNov 2, 202310-Q10-QNov 2, 20238-KCompany UpdateSep 29, 20238-KExecutive ChangeSep 12, 20238-KCompany UpdateAug 22, 20238-KResults of OperationsAug 3, 202310-Q10-QAug 3, 20238-KExecutive Change · Bylaw AmendmentJun 2, 20238-KResults of OperationsMay 11, 202310-Q10-QMay 11, 20238-KResults of OperationsApr 20, 2023DEFA14ADEFA14AApr 14, 2023DEFA14ADEFA14AApr 12, 2023DEF 14ADEF 14AApr 12, 20238-KCompany UpdateMar 17, 20238-KResults of OperationsMar 16, 202310-K10-KMar 16, 20238-KReg FD DisclosureMar 13, 20238-KExecutive ChangeFeb 23, 2023SC 13GSC 13GFeb 1, 2023SC 13GSC 13GJan 13, 20238-KMaterial AgreementJan 6, 2023424B5424B5Jan 6, 2023424B5424B5Jan 4, 20238-KResults of Operations · Company UpdateJan 4, 20238-KCompany UpdateDec 22, 202210-Q10-QNov 7, 20228-KResults of OperationsNov 3, 20228-KExecutive ChangeSep 8, 20228-KCompany UpdateSep 6, 20228-KResults of OperationsAug 11, 2022
Insider Activity
In the 90 days to Feb 18, 2026: 1 sold $19K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Robertson MichelleEVP, CHIEF FINANCIAL OFFICER | Sell | 9,855 | $1.94 | $19K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance